Fintel reports that on December 17, 2025, JP Morgan upgraded their outlook for Recursion Pharmaceuticals (NasdaqGS:RXRX) from ...

GenAI fell short of CEO expectations in 2025, with slower monetization and efficiency gains. Investors focus on ROI, not just ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

American Electric Power Company, Inc. (NASDAQ:AEP) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On ...

Wall Street trading got off to a mixed start on Friday after both the Dow Jones and S&P 500 wrapped up the previous session ...